Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
作者信息
Koopman Wendy, Iakiri Shannon
出版信息
J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):20-1.
PMID:16355554
Abstract
摘要
相似文献
1
Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):20-1.
2
Erythropoietin: high profile, high scrutiny.
J Clin Oncol. 2007 Mar 20;25(9):1021-3. doi: 10.1200/JCO.2006.08.8153. Epub 2007 Feb 20.
3
Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):8-9.
4
New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
J Support Oncol. 2007 Nov-Dec;5(10):471-3.
5
Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Gynecol Oncol. 2006 Jun;101(3):499-502. doi: 10.1016/j.ygyno.2005.11.027. Epub 2006 Jan 10.
6
A multidisciplinary approach for establishing standardized anemia procedures.
J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):18-9.
7
Iron, folate, and cancer-related anemia: perfect together.
J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):16-7.
8
Epoetin alfa and darbepoetin alfa go head to head.
J Clin Oncol. 2006 May 20;24(15):2233-6. doi: 10.1200/JCO.2006.05.7794.
9
Is anemia of cancer different from chemotherapy-induced anemia?
J Clin Oncol. 2008 Mar 1;26(7):1022-4. doi: 10.1200/JCO.2007.15.3874. Epub 2008 Jan 28.
10
Darbepoetin alfa and history of thromboembolic events.
J Clin Oncol. 2009 Nov 20;27(33):e211; author reply e212. doi: 10.1200/JCO.2009.24.6454. Epub 2009 Oct 26.
Zotero 插件